ArticleInternational journal of general medicine2025
Machine Learning-Integrated Analysis of SULF1, CXCL8, and PBLD Expression as Discriminative Biomarkers for Early Detection and Prognosis in Colorectal Cancer.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- V7-DiVA: a feature-based Deep MIL colorectal whole-slide histopathology research platform with blinded external image-input validation.Journal of translational medicine · 2026Article
- Preoperative tumor marker burden score predicts survival in colorectal cancer according to tumor size.BMC cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) is one of the major cancers that threaten human health. Although the CRC census has been gradually popularized, due to the lack of obvious symptoms in the early stage, it is difficult to detect, and the rapid progression and strong metastasis after onset result in a high incidence of CRC. Therefore, the current research aims to identify more powerful molecular targets and biomarkers for the diagnosis, treatment and clinical research of CRC. Methods: The limma package was used to analyze datasets GSE4107, GSE110223, and GSE110224 from the Gene Expression Omnibus (GEO) to identify differentially expressed genes (DEGs) in CRC. Functional enrichment analysis of DEGs was performed using Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG). To further screen for key genes, the DEGs were submitted to the STRING database to construct a protein-protein interaction (PPI) network. Clinical data from The Cancer Genome Atlas (TCGA) database were used to analyze the role of key genes in CRC. Key DEGs were validated using immunohistochemistry, Western blot, and quantitative real-time polymerase chain reaction (RT-qPCR). Survival analysis of key DEGs was performed using the GEPIA database, and survival curves were plotted. The expression levels of DEGs were quantitatively analyzed in samples from 80 CRC patients and 80 healthy controls. Machine learning algorithms were applied to analyze key DEGs and construct a diagnostic model for CRC. A receiver operating characteristic (ROC) curve was plotted to evaluate the performance of the diagnostic model. Results: A total of 981 (GSE4107), 155 (GSE110223), and 280 (GSE110224) DEGs were identified from the GEO databases, among which 152 DEGs were expressed in at least two datasets. GO and KEGG enrichment analyses revealed that these DEGs were widely involved in biological processes such as the muscle system process and extracellular matrix organization. Downregulated genes were involved in pathways including bile secretion and retinol metabolism. PPI network analysis identified 20 overlapping genes, among which CXCL8 and SULF1 were hub up-regulated genes, while PBLD and 17 others were hub down-regulated genes. mRNA-Seq data and RT-qPCR validation showed that CXCL8 and SULF1 were significantly upregulated in CRC samples, whereas PBLD expression levels were higher in normal tissues compared to CRC tissues. Kaplan-Meier curve analysis indicated that high mRNA expression of SULF1 was significantly associated with poorer overall survival in CRC patients, while high mRNA expression of LRRC19 was associated with better overall survival. In contrast, the mRNA expression of CXCL8 and PBLD showed no significant association with overall survival. Gene expression of SULF1 was significantly correlated with disease-free survival, whereas the gene expression of LRRC19, CXCL8, and PBLD showed no significant correlation with disease-free survival. Immunohistochemical analysis further validated the expression levels of SULF1, CXCL8, and PBLD. The machine learning model demonstrated high efficacy in assisting CRC diagnosis, with an AUC value exceeding 0.8, and the most effective model achieved an AUC value greater than 0.9. Decision curve and calibration curve analyses further confirmed its significant clinical net benefit and good consistency. Conclusion: These four identified DEGs (SULF1, CXCL8, LRRC19, and PBLD) may contribute to the treatment of CRC as a new therapeutic target and provide valuable biomarkers for cancer metastasis research.The four identified DEGs were combined with machine learning to construct a CRC diagnostic model with high clinical application value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.